Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target

 
• By David Wild

Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.

After Preparing For Heavy Losses, Bavarian Nordic Set For Growth • Source: Shutterstock

More from Global Vision

More from In Vivo